Articles tagged with Cancer Genomics
Researchers at Jackson Laboratory aim to develop clinical adjuvants that boost vaccine effectiveness in vulnerable populations, with a focus on elderly and immunosuppressed patients. The $3.4 million grant will support the screening of new adjuvant combinations and investigation into their mechanisms of action.
A recent study has identified over 200 proteins involved in cell movement and immune system function that are implicated in ovarian cancer progression. By analyzing the proteomes of 169 ovarian cancer patients, researchers have gained new insights into the biology of the disease and potential targets for treatment.
Scientists analyzed 169 ovarian cancer tumors to identify key proteins, revealing new molecular events in high-grade serous carcinoma. This proteogenomics approach combines genomic and proteomic data to improve understanding of the disease, with potential applications for precision medicine and pharmaceutical interventions.
The LawSeqSM project aims to clarify current genomic law, address gaps, and generate recommendations for a forward-looking legal foundation. This 3-year project brings together experts from academia, industry, and clinical care to create guidance on translating genomics into clinical application.
The Genomic Data Commons (GDC) brings together genomic datasets and analyzes the data using a common set of methods, democratizing the analysis of large cancer genomic datasets. This platform enables researchers to access and share high-quality data, tools, and support to accelerate studies of cancer biology and personalized treatments.
A new research paper by GMU and Inova Health System highlights the importance of proteins in personalized medicine, particularly in cancer treatment. The study suggests that targeting proteins can lead to more effective treatments for patients with metastatic breast cancer.
A new study published in Nature Medicine highlights the potential of big data to unlock the secrets inside cancer cells and enable more effective personalised treatments. The study proposes a blueprint for sharing patient data to improve patient outcomes.
Scientists have found conclusive evidence that a specific jumping gene plays a key role in generating some colon tumors. The study reveals how this gene can trigger cancer by causing mutations in other genes that suppress cancer. Researchers discovered 27 L1 insertions in the tumor, which were not found in surrounding healthy tissue.
Researchers created cell lines with targeted chromosomal deletions to study the role of specific chromosomal losses in cancer development. The findings suggest that chromosomal engineering is a more effective approach than studying individual genes or micro-RNAs.
A study published in Cancer Cell identified a third class of ACC, associated genes, and potential treatment targets. The research aims to provide better treatments for this rare cancer with significant side effects from current therapies.
Researchers found more than half of the genes studied showed sex-biased signatures in certain cancer types, revealing two sex-effect groups associated with distinct incidence and mortality profiles. These findings lay a critical foundation for precision cancer medicine that is sex-specific.
Researchers from 39 institutions worldwide analyzed 91 samples of adrenocortical carcinoma, uncovering double the number of genetic drivers known to fuel adrenal cancer. The study also identified three distinct subtypes of adrenal cancer linked to different outcomes, suggesting a way to use molecular biomarkers for targeted therapy.
Researchers identified three subtypes of ACC with distinct clinical outcomes and molecular alterations. The study also found novel ACC driver genes and suggests that inhibiting whole genome doubling could slow tumor growth. These findings may inform therapeutic decisions and lead to significant advances in patient outcomes.
Researchers have identified five new gene regions associated with an increased risk of developing endometrial cancer, bringing the total number of known risk regions to nine. This discovery doubles the number of genetic risk factors known for the disease, which affects one in four women worldwide.
Researchers developed a new computer algorithm called REVEALER to identify groups of genetic variations associated with cancer cell activation and treatment responses. Using large tumor genomics database The Cancer Genome Atlas, REVEALER revealed new gene mutations linked to cancer development and treatment resistance.
Scientists have identified 182 genome instability suppressing (GIS) genes in yeast and over 400 previously unknown cooperating GIS genes. These findings suggest a complex genetic network maintaining genome integrity and highlight potential therapeutic targets for cancer treatment.
Researchers discover circular RNAs involved in tumor growth and progression, suggesting a new path to cancer treatments. The study provides insights into the role of non-coding RNA in human biology and disease.
Researchers found that cancer cells have a resilient ability to repair nuclear envelope rupture during cell migration, but this process compromises genomic integrity. The study highlights a potential weakness in metastatic cancer cells and an opportunity for developing novel anti-metastatic drugs.
Researchers identified a new subtype of muscle-invasive bladder cancer that resembles some forms of breast cancer, characterized by low levels of the tight junction protein claudin. These claudin-low tumors express high levels of immune-related genes but also show a strong signature of immunosuppression.
Researchers have identified nine distinct subtypes of kidney cancer, each with unique molecular pathways and patient survival outcomes. These findings hold promise for personalized medicine by identifying specific targets for therapies.
A recent paper emphasizes the importance of public health and prevention measures in combating cancer. The authors highlight successes in lung cancer reduction and vaccine development, suggesting that these efforts have brought about significant improvements in mortality rates. By prioritizing prevention, researchers aim to drive meani...
A research team at the University of Tokyo has identified an enzyme called Trimmer, which trims the tails of small RNAs called piRNAs. This process helps regulate jumping genes, or transposons, that can disrupt host genes and contribute to diseases like cancer.
Genomics assessments have identified actionable genetic alterations in pediatric patients with extracranial solid tumors, paving the way for individualized cancer therapy recommendations. Combined tumor and germline whole-exome sequencing has also shown diagnostic yield in children with solid tumors.
A new algorithm has been proposed to automatically search for genes in DNA sequences, making it more efficient and accurate. The BRAKER1 algorithm combines the advantages of existing tools and has already been downloaded by over 1500 laboratories worldwide.
A study found that patients younger than 50 diagnosed with non-small-cell lung cancer have a higher likelihood of having a targetable genomic alteration for which therapies exist. However, they also have an unexpectedly poor prognosis, with median survival rates ranging from 13.6 months for those over 70 to 18.2 months for those under 40.
Moffitt Cancer Center researchers discovered TBK1 plays a novel role in promoting cell division through interacting with CEP170 and NuMA proteins. Disrupting TBK1 activity prevents chromosome separation and mitosis progression.
The current scientific description of the human cell cycle is being revised due to new findings that challenge traditional understanding of DNA replication. Cancer cells exploit an unusual form of DNA replication to bypass genetic changes that cause cancer.
A new study by UC San Francisco scientists shows that the proportion of normal cells in tumor samples can skew genetic analysis results. The team used a massive dataset to examine how tumor purity affects three common genomic methods, revealing potentially disruptive effects on cancer research findings and clinical classifications.
Researchers at UMass Medical School have developed a new CRISPR/Cas9 technology that improves gene editing accuracy by nearly 100 fold. The system combines the CRISPR/Cas9 complex with a programmable DNA-binding domain to verify an additional genetic feature before cutting the genome, reducing off-target changes.
Researchers have discovered a large number of genes that are upregulated in various types of cancer, which could be used to develop early detection tests and targeted therapies. The study, published in Cancer Research, utilized two different technologies to identify 128 markers that were consistently perturbed in both datasets.
The project aims to analyze core replication complexes crucial for repairing damaged DNA and understanding cancer initiation and progression. The study may lead to insights into human health and disease, particularly cancer susceptibility.
Researchers have discovered a new view of how human blood is made, resolving how different kinds of blood cells form quickly from stem cells. This finding has significant implications for understanding and treating blood disorders and diseases.
Scientists have molecularly characterized two types of the second most common kidney cancer, papillary renal cell carcinoma (PRCC), which accounts for 15-20% of kidney cancer cases. The study reveals distinct molecular differences between Type 1 and 2 PRCC, as well as three subtypes of Type 2, each with varying molecular alterations. T...
A mutation in a key enzyme affects sphingolipid levels, leading to neurodegeneration. Researchers found that increased 20-carbon sphingolipids cause problems with neuronal membranes.
A new procedure called CAUSEL uses genetic fine mapping, epigenomic profiling, epigenomic editing, genome editing, and phenotypic analysis to pinpoint disease-causing variants in non-coding genomes. The approach has shown promise in identifying disease-associated variants in prostate cancer risk.
The University of Maryland has received a $1.8 million grant from the National Institutes of Health to improve Bioconductor, an open-source data visualization software used in genomic marker identification for cancer and other diseases.
Krishnakumar Kizhatil has been awarded the prestigious Lewis Rudin Glaucoma Prize for his research on Schlemm's canal, a unique vessel that plays a key role in glaucoma. The prize recognizes Kizhatil's work as a major breakthrough in understanding the molecular basis of intraocular pressure elevation and its link to glaucoma.
A new method for personalizing bladder cancer treatments has been developed by researchers at the University of California - Davis Health. The approach uses tumor xenografts to identify effective therapies, which can be tested in mice before being administered to patients.
A study found a significant association between long telomere length and increased risk of lung adenocarcinoma. Long telomeres were associated with more rounds of cell division, potentially allowing for more opportunities to accumulate carcinogenic mutations.
The MD Anderson Cancer Center has been selected as a Genome Characterization Center to analyze patient samples from multiple NCI programs. The center will focus on functional proteomics, enabling the study of protein expression and modification in cancer tumors.
A study of 85 common chemicals found that 50 disrupted cell function in ways correlated with early cancer patterns. The researchers suggest these molecules may be acting in synergy to increase cancer activity.
Researchers at PolyU have developed a novel big data analysis platform that unveils the unregulated patterns of gene network in cancer. The platform discovers potential diagnostic and therapeutic target genes, including Nucleophosmin (NPM1), for Chronic Myelogenous Leukemia (CML).
Researchers identified four melanoma subtypes, including BRAF, RAS, NF1 and Triple-WT, through analysis of 331 patient samples. These subtypes share common signaling pathways but differ in activation, suggesting potential for targeted therapies.
Scientists detected a distinct accumulation of mutations at sites where CTCF and cohesin bind DNA, protecting these sites from mutations. The study's findings reveal new insights into the regulation of gene expression and chromatin structure in cancer.
A new study suggests that cell fusion can initiate cancerous processes and tumor formation through 'genomic catastrophe', leading to chromosomal instability and DNA damage. Fused cells from rat intestinal epithelial cells formed tumors in immunodeficient mice, providing evidence for a molecular mechanism driving neoplastic transformation.
Researchers found that Non-Invasive Prenatal Testing (NIPT) can detect maternal cancers at an early stage, before symptoms appear. The study identified three different early-stage cancers in three women and showed the potential of NIPT for non-invasive cancer screening.
The Jackson Laboratory will receive a $100,000 grant from The Arthur Vining Davis Foundations to support its 'Teaching the Genome Generation' program, which provides hands-on lab experience for high school science and math teachers. This program aims to prepare students for careers in genome-based healthcare.
A new genomic test has been validated for detecting lung cancer with high sensitivity, allowing physicians to identify patients at low probability of having the disease. This test can spare patients from costly and risky procedures, improving diagnosis and patient anxiety.
A study published by the GTEx Project Consortia reveals that gene expression variation differs more between organs than individuals, with over 750 genes linked to sex and ethnicity. The research also found that 2,000 genes vary with age, including those related to neurodegenerative diseases.
Researchers at the University of Utah Health have discovered patterns in DNA anomalies that predict a woman's outcome significantly better than tumor stage, also indicating how well she'll respond to platinum therapy. The new method could lead to personalized prognostic and diagnostic laboratory tests.
Researchers at the University of Texas MD Anderson Cancer Center review the potential of combining genomically targeted therapies with immune checkpoint blockade drugs to attack cancer. The approach shows promise, but more support is needed to accelerate progress and minimize side effects.
Dr. William Hahn receives the 39th annual AACR-Rosenthal Memorial Award for his seminal work on cancer initiation, maintenance, and progression. His research provides a foundation for novel therapeutic approaches now being tested in the clinic.
A multi-disciplinary team from Singapore has characterised genetic changes associated with liver metastasis in colorectal cancer, enabling the development of personalised diagnostic tests. The research could lead to improved treatment and cure rates for patients.
Berkeley Lab scientists discovered that genetic makeup affects cancer risk from low-dose radiation, identifying key regions in the genome and tumor microenvironment. The findings could lead to genetic screening tests to identify people at high risk of cancer after exposure.
A study published in JNCI found that most online cancer care websites offer nonstandard and unvalidated genetic tests, despite marketing them as personalized and effective. The vast majority of companies promoting these tests do not have evidence to support their clinical utility.
Researchers have generated and analyzed reference epigenome maps for 111 human cell types, revealing the complex interplay between genetic and environmental factors in shaping our genome. This breakthrough has significant implications for understanding and treating diseases such as cancer and Alzheimer's.
A study published in JAMA Oncology found that at least one clinically relevant genomic alteration was present in most samples tested, suggesting a potential for personalized therapy. The research analyzed 200 cancer of unknown primary site (CUP) samples and identified 169 specimens with potentially targetable genomic alterations.
Researchers found that non-mutated CLL shows increased gene expression variability, while mutated leukaemia has lower variability. This variation is linked to tumour aggressiveness and may help predict disease subtype.
Scientists have made the largest ever catalogue of biological chimeras available to the public domain. The new database comprises over 29,000 small RNA molecules that originate from different genomic regions, which could reveal useful markers for clinical oncology practice and novel drug targets for cancer treatment.
A comprehensive catalog of genetic mutations has been published for 279 head and neck cancers, revealing distinct genetic profiles for HPV-positive and -negative patients. This finding may lead to the development of targeted therapies and improved outcomes for these cancer types.